We have recently shown that increased STAT3 activity correlates with chemoradiotherapy resistance in rectal and esophageal cancer cells, and that inhibition of the IL-6/STAT3 pathway results in sensitization to CRT [21,22]. This evidence concerns the gene IL6 and esophageal cancer.